"Yuantai Pharmaceuticals' mid-term revenue reaches a record high in 2025."

On August 19, YuanDa Pharmaceuticals announced its mid-term performance for 2025, with a revenue of 6.11 billion Hong Kong dollars, reaching a new high. Among them, the revenue from innovative and barrier products accounted for approximately 51%, an increase of nearly 15 percentage points year-on-year. Excluding the impact of centralized procurement and exchange rates, the company's revenue increased by about 13% year-on-year; the company achieved a net profit of approximately 1.17 billion Hong Kong dollars during the period. In terms of innovation research and development, the company's total investment in research and projects during the period was approximately 1.02 billion Hong Kong dollars, achieving progress in 38 major milestones. Currently, YuanDa Pharmaceuticals has a total of 42 innovative projects in reserve.